Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a Medicaid managed care population: African Americans versus Caucasians

Pain Medicine

Volumn 6, Issue 1, 2005, Pages 11-17

  Shaya, Fadia T ^a   Blume, Steven ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cyclooxygenase 2 (COX 2); Drug utilization; Nonsteroidal anti inflammatory agent (NSAID); Pain; Prescribing behavior; Racial and ethnic disparities

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AFRICAN AMERICAN; AGE; ANTICOAGULATION; ARTICLE; BACKACHE; CAUCASIAN; CHRONIC PAIN; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDICATION; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OSTEOARTHRITIS; PAIN; PREDICTION; PRESCRIPTION; PROBABILITY; RACE; RACE DIFFERENCE; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG UTILIZATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICAID; MIDDLE AGED; PAIN; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 14944347620     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2005.05011.x     Document Type: Article

References (22)

1. The Institute of Medicine. Unequal treatment: Confronting racial and ethnic disparities in health care. Washington, DC: National Academy of Sciences; 2002.
2. U.S. Department of Health and Human Services. The initiative to eliminate racial and ethnic disparities in health. Washington, DC: U.S. Government Printing Office; February 21, 1999.
3. U.S. Department of Health and Human Services. Healthy people 2010. 2nd edition. Washington, DC: U.S. Government Printing Office; November 2000.
4. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. National healthcare disparities report. Washington, DC: U.S. Government Printing Office; December 2003. Available at: http://www.qualitytools.ahrq.gov/disparitiesreport/download_report.aspx (accessed May 2004).
5. Maryland Statute 20-904. Maryland office of minority health and health disparities. Signed May 11, 2004.
6. Green CR, Anderson KO, Baker TA, et al. Review article: The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 2003;4(3):277-94.
7. Bonham VL. Race, ethnicity, and pain treatment: Striving to understand the causes and solutions to the disparities in pain treatment. J Law Med Ethic 2001;29:52-68.
8. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618-26.
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA 2000;284(10):1247-55.
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: The VIGOR Study Group. N Engl J Med 2000; 343(21):1520-8.
11. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum 2002;46:328-46.
12. Shaya FT, Wong W, Shin J, Martin L, Samant N. Formulary decision-making considerations: Cox-2 inhibitors. Managed Care Interface 2004; 11:29-41.
13. Green CR, Baker TA, Sato Y, Washington TL, Smith EM. Race and chronic pain: A comparative study of young black and white Americans presenting for management. J Pain 2003;4:176-83.
14. Kaplan GA, Keil JE. Special report: Socioeconomic factors and cardiovascular disease: A review of the literature. Circulation 1993;88(4):1973-98.
15. Dominick KL, Dudley TK, Grambow SC, et al. Racial differences in health care utilization among patients with osteoarthritis. J Rheumatol 2003; 30(10):2201-6.
16. Khandker RK, Simoni-Wastila LJ. Difference in prescription drug utilization and expenditures between blacks and whites in the Georgia Medicaid population. Inquiry Spring 1998;35:78-87.
17. Chen A, Chang RR. Factors associated with prescription drug expenditures among children: An analysis of the medical expenditure panel survey. Pediatrics 2002;109(5):728-32.
18. Briesacher B, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ Rev 2003-2004;25(2):63-76.
19. Peterson M. Two big selling arthritis drugs are questioned. New York Times. June 4, 2002.
20. Solomon DH, Schneeweiss S, Glynn R, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important? Am J Med 2003;115:715-20.
21. Doshi JA, Brandt N, Stuart B. The impact of drug coverage on COX-2 inhibitor use in Medicare. Health Aff 2004;W4:94-105.
22. Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL. "We don't carry that" - Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med 2000; 342:1023-6.